To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

Inclusion Criteria: * Voluntarily participate in the clinical trial and sign the informed consent form, with full understanding of the trial content, procedures, and potential adverse reactions. * Patients (including partners) have no pregnancy plans or sperm/egg donation plans from screening until 6 months after the last dose of the investigational drug, and agree to use effective contraception. * Aged 18-75 years (inclusive), regardless of gender. * Male participants weigh ≥50.0 kg; female participants weigh ≥45.0 kg. Body mass index (BMI) = weight (kg)/height² (m²), with BMI ranging 18.0-32.0 kg/m² (inclusive). * Patients can communicate effectively with investigators and comply with the trial protocol. Additional Criteria for Participants with Normal Liver Function: * Negative serum HBsAg and Hepatitis C Virus (HCV) antibody test results. * Weight within ±10 kg of the average weight of groups A/B; age within ±10 years of the average age of groups A/B; gender distribution similar to groups A/B (±1 participant per gender). Additional Criteria for Participants with Impaired Liver Function: * Chronic liver injury caused by primary liver diseases (e.g., hepatitis B/C, non-alcoholic fatty liver disease, alcoholic liver disease) or clinically diagnosed cirrhosis, classified as Child-Pugh Grade A or B. * Stable condition within 2 weeks prior to dosing as judged by the investigator. * No medication within 4 weeks before screening, or stable treatment regimen for underlying di…